Compare EVI & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVI | ARMP |
|---|---|---|
| Founded | 1959 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 204.6M | 199.7M |
| IPO Year | 1995 | 1996 |
| Metric | EVI | ARMP |
|---|---|---|
| Price | $21.33 | $3.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $17.50 |
| AVG Volume (30 Days) | 57.1K | ★ 92.4K |
| Earning Date | 11-13-2026 | 11-11-2026 |
| Dividend Yield | ★ 1.52% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.48 | N/A |
| Revenue | ★ $389,830,000.00 | N/A |
| Revenue This Year | $8.40 | N/A |
| Revenue Next Year | $4.71 | N/A |
| P/E Ratio | $45.63 | ★ N/A |
| Revenue Growth | ★ 10.26 | N/A |
| 52 Week Low | $12.75 | $2.75 |
| 52 Week High | $29.36 | $14.98 |
| Indicator | EVI | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 70.70 | 42.33 |
| Support Level | $18.15 | $2.75 |
| Resistance Level | $23.92 | $5.63 |
| Average True Range (ATR) | 0.94 | 0.37 |
| MACD | 0.13 | 0.05 |
| Stochastic Oscillator | 75.88 | 41.55 |
EVI Industries Inc is a value-added distributor and service provider in the commercial laundry industry. It sells and leases commercial laundry equipment, specializing in washing, drying, finishing, material handling, water heating, power generation, and water reuse applications. The company supports its equipment offerings with installation, maintenance, and repair services through a large network of trained technicians. It serves a wide range of customers, including commercial, industrial, institutional, government, and retail sectors. Geographically, the company serves various countries including United States, Canada, the Caribbean, and Latin America.
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.